What is the Purpose of this Study?
To evaluate the long-term safety and tolerability of tulisokibart
Eligibility
- * Has participated in a qualifying tulisokibart Phase 2 or Phase 3 parent study for CD or UC
- * The investigator determines that the participant derives clinical benefit from continued study intervention based upon clinical evaluations performed during their parent study
- * A participant assigned female sex at birth is not breastfeeding during the study intervention period and for at least 14 weeks after the last dose of study intervention
- * A participant of childbearing potential (POCBP) is not pregnant and has a negative highly sensitive pregnancy test (urine or serum) as required by local regulations within 24 hours (for a urine test) or 72 hours (for a serum test) before the first dose of study intervention
Where can I participate?
Beverly
More about this Clinical Trial
What is the full name of this clinical trial?
A Phase 3 Extension Study to Evaluate the Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn?s Disease or Ulcerative Colitis